Literature DB >> 22019703

IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization.

Kai-ping Han1, Xiaoyun Zhu, Bai Liu, Emily Jeng, Lin Kong, Jason L Yovandich, Vinay V Vyas, Warren D Marcus, Pierre-Andre Chavaillaz, Christian A Romero, Peter R Rhode, Hing C Wong.   

Abstract

IL-15, a promising cytokine for treating cancer and viral diseases, is presented in trans by the IL-15 receptor (IL-15R) alpha-chain to the IL-15Rβγc complex displayed on the surface of T cells and natural killer (NK) cells. We previously reported that an asparagine to aspartic acid substitution at amino acid 72 (N72D) of IL-15 provides a 4-5-fold increase in biological activity compared to the native molecule. In this report, we describe Chinese hamster ovary (CHO) cell expression of a soluble complex (IL-15 N72D:IL-15RαSu/Fc) consisting of the IL-15 N72D superagonist and a dimeric IL-15Rα sushi domain-IgG1 Fc fusion protein. A simple but readily scalable affinity and ion exchange chromatography method was developed to highly purify the complex having both IL-15 binding sites fully occupied. The immunostimulatory effects of this complex were confirmed using cell proliferation assays. Treatment of mice with a single intravenous dose of IL-15N72D:IL-15RαSu/Fc resulted in a significant increase in CD8+ T cells and NK cells that was not observed following IL-15 treatment. Pharmacokinetic analysis indicated that the complex has a 25-h half-life in mice which is considerably longer than <40-min half-life of IL-15. Thus, the enhanced activity of the IL-15N72D:IL-15RαSu/Fc complex is likely the result of the increased binding activity of IL-15N72D to IL-15Rβγc, optimized cytokine trans-presentation by the IL-15RαSu domain, the dimeric nature of the cytokine domain and its increased in vivo half-life compared to IL-15. These findings indicate that this IL-15 superagonist complex could serve as a superior immunostimulatory therapeutic agent.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22019703      PMCID: PMC3221918          DOI: 10.1016/j.cyto.2011.09.028

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  20 in total

1.  Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}.

Authors:  Mark P Rubinstein; Marek Kovar; Jared F Purton; Jae-Ho Cho; Onur Boyman; Charles D Surh; Jonathan Sprent
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-06       Impact factor: 11.205

2.  Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.

Authors:  Thomas A Stoklasek; Kimberly S Schluns; Leo Lefrançois
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

3.  Potent antitumor activity of a tumor-specific soluble TCR/IL-2 fusion protein.

Authors:  Heather J Belmont; Shari Price-Schiavi; Bai Liu; Kimberlyn F Card; Hyung-Il Lee; Kai-Ping Han; Jinghai Wen; Shamay Tang; Xiaoyung Zhu; Jane Merrill; Pierre-Andre Chavillaz; Jeffrey L Wong; Peter R Rhode; Hing C Wong
Journal:  Clin Immunol       Date:  2006-06-30       Impact factor: 3.969

4.  Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins.

Authors:  Erwan Mortier; Agnès Quéméner; Patricia Vusio; Inken Lorenzen; Yvan Boublik; Joachim Grötzinger; Ariane Plet; Yannick Jacques
Journal:  J Biol Chem       Date:  2005-11-11       Impact factor: 5.157

5.  Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions.

Authors:  Marybeth S Hughes; Yik Y L Yu; Mark E Dudley; Zhili Zheng; Paul F Robbins; Yong Li; John Wunderlich; Robert G Hawley; Morvarid Moayeri; Steven A Rosenberg; Richard A Morgan
Journal:  Hum Gene Ther       Date:  2005-04       Impact factor: 5.695

Review 6.  The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design.

Authors:  Thomas A Waldmann
Journal:  Nat Rev Immunol       Date:  2006-08       Impact factor: 53.106

Review 7.  Twelve immunotherapy drugs that could cure cancers.

Authors:  Martin A Cheever
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

8.  Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells.

Authors:  Mathieu Epardaud; Kutlu G Elpek; Mark P Rubinstein; Ai-ris Yonekura; Angelique Bellemare-Pelletier; Roderick Bronson; Jessica A Hamerman; Ananda W Goldrath; Shannon J Turley
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

9.  Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity.

Authors:  Cristina Bergamaschi; Margherita Rosati; Rashmi Jalah; Antonio Valentin; Viraj Kulkarni; Candido Alicea; Gen-Mu Zhang; Vainav Patel; Barbara K Felber; George N Pavlakis
Journal:  J Biol Chem       Date:  2007-11-30       Impact factor: 5.157

10.  Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action.

Authors:  Sigrid Dubois; Hiral J Patel; Meili Zhang; Thomas A Waldmann; Jürgen R Müller
Journal:  J Immunol       Date:  2008-02-15       Impact factor: 5.422

View more
  86 in total

1.  The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.

Authors:  Maximillian Rosario; Bai Liu; Lin Kong; Lynne I Collins; Stephanie E Schneider; Xiaoyue Chen; Kaiping Han; Emily K Jeng; Peter R Rhode; Jeffrey W Leong; Timothy Schappe; Brea A Jewell; Catherine R Keppel; Keval Shah; Brian Hess; Rizwan Romee; David R Piwnica-Worms; Amanda F Cashen; Nancy L Bartlett; Hing C Wong; Todd A Fehniger
Journal:  Clin Cancer Res       Date:  2015-09-30       Impact factor: 12.531

2.  IL-15 Superagonist-Mediated Immunotoxicity: Role of NK Cells and IFN-γ.

Authors:  Yin Guo; Liming Luan; Whitney Rabacal; Julia K Bohannon; Benjamin A Fensterheim; Antonio Hernandez; Edward R Sherwood
Journal:  J Immunol       Date:  2015-07-27       Impact factor: 5.422

3.  In Vivo Activation of Human NK Cells by Treatment with an Interleukin-15 Superagonist Potently Inhibits Acute In Vivo HIV-1 Infection in Humanized Mice.

Authors:  Kieran Seay; Candice Church; Jian Hua Zheng; Kathryn Deneroff; Christina Ochsenbauer; John C Kappes; Bai Liu; Emily K Jeng; Hing C Wong; Harris Goldstein
Journal:  J Virol       Date:  2015-04-01       Impact factor: 5.103

4.  A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice.

Authors:  Andrew Yee; Robert D Gildersleeve; Shufang Gu; Colin A Kretz; Beth M McGee; Keisha M Carr; Steven W Pipe; David Ginsburg
Journal:  Blood       Date:  2014-05-21       Impact factor: 22.113

Review 5.  Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens.

Authors:  Richard W Childs; Mattias Carlsten
Journal:  Nat Rev Drug Discov       Date:  2015-05-22       Impact factor: 84.694

6.  Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models.

Authors:  Peter R Rhode; Jack O Egan; Wenxin Xu; Hao Hong; Gabriela M Webb; Xiaoyue Chen; Bai Liu; Xiaoyun Zhu; Jinghai Wen; Lijing You; Lin Kong; Ana C Edwards; Kaiping Han; Sixiang Shi; Sarah Alter; Jonah B Sacha; Emily K Jeng; Weibo Cai; Hing C Wong
Journal:  Cancer Immunol Res       Date:  2015-10-28       Impact factor: 11.151

7.  Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy.

Authors:  Jeffrey Schlom; Duane H Hamilton; Karin L Lee; Stephen C Benz; Kristin C Hicks; Andrew Nguyen; Sofia R Gameiro; Claudia Palena; John Z Sanborn; Zhen Su; Peter Ordentlich; Lars Rohlin; John H Lee; Shahrooz Rabizadeh; Patrick Soon-Shiong; Kayvan Niazi
Journal:  Cancer Immunol Res       Date:  2019-07-10       Impact factor: 11.151

Review 8.  Immunogenomic Analysis of Exceptional Responder to ALT-803 (IL-15 Analogue) in BCG Unresponsive Nonmuscle Invasive Bladder Cancer: A Case Series and Review of the Literature.

Authors:  Jeffrey Huang; Stephen L Shiao; Hideki Furuya; Charles J Rosser
Journal:  J Immunother       Date:  2019 Nov/Dec       Impact factor: 4.456

Review 9.  Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression.

Authors:  Naeem K Patil; Julia K Bohannon; Edward R Sherwood
Journal:  Pharmacol Res       Date:  2016-07-25       Impact factor: 7.658

10.  ALT-803 Transiently Reduces Simian Immunodeficiency Virus Replication in the Absence of Antiretroviral Treatment.

Authors:  Amy L Ellis-Connell; Alexis J Balgeman; Katie R Zarbock; Gabrielle Barry; Andrea Weiler; Jack O Egan; Emily K Jeng; Thomas Friedrich; Jeffrey S Miller; Ashley T Haase; Timothy W Schacker; Hing C Wong; Eva Rakasz; Shelby L O'Connor
Journal:  J Virol       Date:  2018-01-17       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.